Another in vivo study reported obvious anti-osteolytic effects of BHQ880 in the 5T2MM murine model of myeloma, with concurrent protection against 5T2MM-induced trabecular bone loss, but BHQ880 treatment to inhibit DKK1 did not reduce tumor burden (Heath et al., 2009). The gene discussed is DKK1; the disease is neoplasm.